Alzamend Neuro terminates ATM equity program after raising ~$1.3M at ~$1.20/share

Alzamend Neuro, Inc.

Terminated ATM agreement with Ascendiant Capital Markets effective May 16, 2024.
Sold 1,076,821 shares and raised approximately $1.3 million in gross proceeds (~$1.20 per share).
Company cited limiting uncertainty and unfavorable dilution for stockholders as reason for termination.
No further sales will be made under the ATM facility; all obligations cease upon termination.
Clinical-stage biotech focused on Alzheimer's, bipolar, MDD, and PTSD treatments.

item 1.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Alzamend Neuro, Inc. terminated Agreement with Ascendiant Capital Markets, LLC (effective 2024-05-16).

Action: termination
Agreement: atm program
Counterparty: Ascendiant Capital Markets, LLC
Effective: 2024-05-16

Exact text from the filing

Item 1.02 Termination of a Material Agreement On May 6, 2024, Alzamend Neuro, Inc. (the “ Company ”) provided written notice to Ascendiant Capital Markets, LLC, as sales agent (the “ Agent ”) of its election to terminate the At-the-Market (“ ATM ”) Issuance Sales Agreement (the “ Agreement” ), dated September 8, 2023, between the Company and the Agent with regards to sales of the Company’s common stock under the Agreement. The Company had sold 1.08 million shares of common stock and raised approximately $1.3 million in gross proceeds, or approximately $1.20 per share, under the ATM. The termination is effective as of May 16, 2024. The material terms of the Agreement are summarized in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 8, 2023.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-24-008531

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.